Investigating how selective autophagy can reduce neurotoxicity in Huntington's disease.
Determining Selective Autophagy Kinase in Modulating Neurotoxicity in Huntington's Disease Model
This study is looking into how a natural process in the body can help protect brain cells in people with Huntington's disease by clearing out harmful proteins, with the hope of finding new ways to treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10881922 on NIH RePORTER |
What this research studies
This research aims to understand the molecular mechanisms behind neuroprotective autophagy in Huntington's disease (HD) and explore its potential as a therapeutic target. Huntington's disease is caused by a genetic mutation that leads to toxic protein accumulation in the brain. The study focuses on how selective autophagy can clear these harmful proteins, specifically the mutant huntingtin protein, which is responsible for the disease's neurotoxicity. By examining the role of specific proteins involved in the autophagy process, the research seeks to identify new treatment strategies that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington's disease, particularly those experiencing early to moderate symptoms.
Not a fit: Patients with advanced Huntington's disease or those without the genetic mutation associated with the condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively reduce neurotoxicity and slow the progression of Huntington's disease.
How similar studies have performed: Previous research has shown promise in targeting autophagy pathways for neurodegenerative diseases, indicating that this approach may yield significant advancements.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Yue, Zhenyu — Icahn School of Medicine at Mount Sinai
- Study coordinator: Yue, Zhenyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.